JP2015504514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504514A5 JP2015504514A5 JP2014541200A JP2014541200A JP2015504514A5 JP 2015504514 A5 JP2015504514 A5 JP 2015504514A5 JP 2014541200 A JP2014541200 A JP 2014541200A JP 2014541200 A JP2014541200 A JP 2014541200A JP 2015504514 A5 JP2015504514 A5 JP 2015504514A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- item
- treatment
- gag
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 90
- 239000000090 biomarker Substances 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 35
- 208000011580 syndromic disease Diseases 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 21
- 210000004556 brain Anatomy 0.000 claims description 16
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 14
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000013068 control sample Substances 0.000 claims description 6
- 238000002641 enzyme replacement therapy Methods 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 238000007913 intrathecal administration Methods 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000004797 therapeutic response Effects 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 210000001638 cerebellum Anatomy 0.000 claims description 2
- 230000001054 cortical effect Effects 0.000 claims description 2
- 210000004884 grey matter Anatomy 0.000 claims description 2
- 230000004766 neurogenesis Effects 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 11
- 208000005340 mucopolysaccharidosis III Diseases 0.000 claims 6
- 208000011045 mucopolysaccharidosis type 3 Diseases 0.000 claims 6
- 238000002716 delivery method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 10
- 102000016838 Calbindin 1 Human genes 0.000 description 8
- 108010028310 Calbindin 1 Proteins 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 1
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556810P | 2011-11-07 | 2011-11-07 | |
| US61/556,810 | 2011-11-07 | ||
| US201261584165P | 2012-01-06 | 2012-01-06 | |
| US61/584,165 | 2012-01-06 | ||
| PCT/US2012/063935 WO2013070760A1 (en) | 2011-11-07 | 2012-11-07 | Biomarkers for sanfilippo syndrome and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504514A JP2015504514A (ja) | 2015-02-12 |
| JP2015504514A5 true JP2015504514A5 (enExample) | 2015-12-24 |
Family
ID=48280853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541200A Pending JP2015504514A (ja) | 2011-11-07 | 2012-11-07 | サンフィリポ症候群のためのバイオマーカーおよびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130121984A1 (enExample) |
| EP (1) | EP2776553B1 (enExample) |
| JP (1) | JP2015504514A (enExample) |
| CN (1) | CN104114686A (enExample) |
| AU (1) | AU2012335890A1 (enExample) |
| CA (1) | CA2854333A1 (enExample) |
| WO (1) | WO2013070760A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2891522A1 (en) * | 2012-12-07 | 2014-06-12 | Shire Human Genetic Therapies, Inc. | Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia |
| JP2017531632A (ja) * | 2014-09-29 | 2017-10-26 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | ムコ多糖症ｉｉｉｂ型（ｍｐｓｉｉｉｂ）を治療する方法 |
| MA40954A (fr) * | 2014-11-14 | 2017-09-19 | Shire Human Genetic Therapies | Détermination de niveaux de glycosaminoglycane par spectrométrie de masse |
| WO2017132675A1 (en) * | 2016-01-29 | 2017-08-03 | Alexion Pharmaceuticals, Inc. | Enzyme replacement therapy in mucopolysaccharidosis iiib patients |
| EP3684463B1 (en) | 2017-09-19 | 2025-05-14 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| CN112578123B (zh) * | 2019-09-27 | 2022-10-25 | 成都中医药大学 | 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7015037B1 (en) * | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
| US20050055733A1 (en) * | 2001-07-06 | 2005-03-10 | Zairen Sun | Small intestine and colon genes |
| EP1497650A4 (en) * | 2002-04-30 | 2008-04-02 | Seikagaku Kogyo Co Ltd | METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES |
| AUPS293002A0 (en) * | 2002-06-14 | 2002-07-04 | Women's And Children's Hospital | Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| WO2007065273A1 (en) * | 2005-12-08 | 2007-06-14 | The University Of British Columbia | Mucopolysaccharidosis (mps) diagnostic methods, systems, kits and assays associated therewith |
| US20070161074A1 (en) * | 2005-12-27 | 2007-07-12 | Daiichi Pharmaceutical Co., Ltd. | Diagnostic method of mucopolysaccharidoses |
| US8183003B2 (en) * | 2009-01-02 | 2012-05-22 | Zacharon Pharmaceuticals, Inc. | Polymer end group detection |
| US9029530B2 (en) * | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
-
2012
- 2012-11-07 US US13/671,302 patent/US20130121984A1/en not_active Abandoned
- 2012-11-07 WO PCT/US2012/063935 patent/WO2013070760A1/en not_active Ceased
- 2012-11-07 EP EP12847544.9A patent/EP2776553B1/en active Active
- 2012-11-07 CA CA2854333A patent/CA2854333A1/en not_active Abandoned
- 2012-11-07 CN CN201280065796.8A patent/CN104114686A/zh active Pending
- 2012-11-07 JP JP2014541200A patent/JP2015504514A/ja active Pending
- 2012-11-07 AU AU2012335890A patent/AU2012335890A1/en not_active Abandoned
-
2016
- 2016-06-16 US US15/184,731 patent/US20170131293A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504514A5 (enExample) | ||
| CN111662982B (zh) | 用于脑胶质瘤早期诊断和/或复发监测的生物标志物及其应用 | |
| CN104651513B (zh) | 一种痛风血清miRNAs生物标志物及其表达量的检测方法 | |
| Tan et al. | Loss of Twist1 in the mesenchymal compartment promotes increased fibrosis in experimental lung injury by enhanced expression of CXCL12 | |
| CN111748618A (zh) | 一种帕金森病早期诊断的生物标志物及其应用 | |
| KR102178922B1 (ko) | 당뇨병성 신증 진단을 위한 마이크로RNA let-7 또는 마이크로RNA-150 바이오마커 및 이의 용도 | |
| CN112195244A (zh) | Gmfb作为肝细胞肝癌生物标志物的应用 | |
| CN110016504B (zh) | CDR1as在神经管畸形产前筛查中的应用、神经管畸形产前筛查的产品和方法 | |
| CN106434872A (zh) | 一种诊断2型糖尿病的miRNA分子标志物hsa‑miR‑152‑3p及其应用 | |
| Ye et al. | Preeclampsia is associated with decreased methylation of the GNA12 promoter | |
| CN115747324A (zh) | circRNA circS100A11的应用 | |
| JP2019187413A (ja) | ループス腎炎の検出またはそのリスクを予測する方法およびその応用 | |
| US20120231460A1 (en) | Method and Apparatus for Predicting Pharmacological Efficacy of Human Anti-TNFa Antibody Drug against Rheumatoid Arthritis | |
| KR102257123B1 (ko) | 난소암의 진단 또는 모니터링 방법 | |
| KR102178919B1 (ko) | 당뇨병성 신증 진단을 위한 마이크로rna 바이오마커 및 이의 용도 | |
| JP2022500020A (ja) | リンパ系疾患の診断および治療のための組成物および方法 | |
| CN116492463B (zh) | Cd155分子在肝纤维化领域中的应用 | |
| CN113403390B (zh) | lncRNA在儿童心肌炎诊治中的应用 | |
| CN109609620B (zh) | 用于辅助诊断血行播散型肺结核的试剂盒 | |
| JP3901684B2 (ja) | 神経芽腫の体液による検査方法 | |
| CN114181940A (zh) | CircN4bp1的SiRNA在制备治疗脓毒症致ARDS药物中的应用 | |
| CN108384848A (zh) | 血清中circ_0021132作为深静脉血栓形成诊断标志物的应用 | |
| CN108424960A (zh) | 一种LncRNA作为深静脉血栓形成诊断标志物的应用 | |
| CN118291606B (zh) | Rna组合及其在复发性流产诊断标记物中的应用 | |
| CN108424963A (zh) | 血清中circ_0079591作为URSA诊断及妊娠结局评估标志物的应用 |